Steve Schonfeld’s EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share EQHA.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-19,862
Closed -$2K 3342
2022
Q3
$2K Hold
19,862
﹤0.01% 2833
2022
Q2
$2K Buy
+19,862
New +$4.11K ﹤0.01% 2422

Other funds holding EQHA.WS

Steve Schonfeld's EQHA.WS Position: Q4 2022 in Review

Steve Schonfeld sold out of EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share (EQHA.WS) in Q4 2022, closing a stake of 19,862 shares — an estimated $2K sold.

Steve Schonfeld first reported a position in EQHA.WS in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 1 fund tracked by Wall St. Rank holds EQHA.WS as of Q4 2022.

  • Steve Schonfeld reported no remaining EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
  • Steve Schonfeld sold 19,862 EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share shares in Q4 2022, an estimated $2K.
  • Steve Schonfeld first reported a position in EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share in Q2 2022 and held it in 2 quarters.
  • Steve Schonfeld's EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share position peaked at $2K in Q3 2022.
  • 1 fund tracked by Wall St. Rank held EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.